GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) have submitted data from the landmark Impact trial to the FDA in the hopes of landing an expanded label for the Trelegy Ellipta triple inhaler.
The two companies are hoping that their therapy could be used to treat airflow obstruction and to reduce exacerbations in people with chronic obstructive pulmonary disease.
Get the full story at our sister site, Drug Delivery Business News.
The post GSK, Innoviva seek expanded label for triple inhaler appeared first on MassDevice.